dabur

Est.1979

Providing Integrated Research Solutions in Preclinical Biology

sir
We offer a comprehensive repertoire of cell biology-based methods & models to delineate the molecular action of NCEs or novel formulations. Our assay development team can customize a range of in vitro, ex vivo and in vivo cell-based models to establish the key cellular pathways determining the pharmacology of the lead molecules. The designing of methodologies focuses on the evaluation of the NCEs, Phytochemicals, or differentiated formulations. These mechanistic studies may be useful for selection of pharmacodynamic endpoints.  One or more of the following strategies is/are followed to profile the molecule under investigation.
Oncology
Metabolic Disease
Inflammation
Immunomodulation
In Vitro Cosmetic Screens
Fertility
Gastrointestinal
Other
We offer a comprehensive repertoire of cell biology-based methods & models to delineate the molecular action of NCEs or novel formulations. Our assay development team can customize a range of in vitro, ex vivo and in vivo cell-based models to establish the key cellular pathways determining the pharmacology of the lead molecules. The designing of methodologies focuses on the evaluation of the NCEs, Phytochemicals, or differentiated formulations. These mechanistic studies may be useful for selection of pharmacodynamic endpoints.  One or more of the following strategies is/are followed to profile the molecule under investigation.
Oncology
Metabolic Disease
Inflammation
Immunomodulation
In Vitro Cosmetic Screens
Fertility
Gastrointestinal
Other
Our preclinical In Vivo research platform is currently focused in the therapeutic areas of Oncology, Metabolic Diseases, Inflammation, Hair Biology, Derma Pathology, Fertility, Gastrointestinal issues.
Oncology
Metabolic Disease
Inflammation
Neurology
Pain
GI Health
Covid 19
Dermatology
Invivo-others
Toxicology Department of Dabur Research Foundation (DRF) has extensive expertise to design and conduct toxicity studies with various routes of administration viz., oral, topical, intravenous, subcutaneous, intraperitoneal, intramuscular covering all kinds of test products such as Pharmaceuticals, biopharmaceuticals, phytopharmaceuticals, herbals, agrochemicals, cosmeceuticals, differentiated formulations, specialty chemicals following International and Nationals Guidelines such as ICH, EMEA, WHO, OECD, EU, OPPTS and Schedule Y, CIB, AYUSH (CCRAS) respectively. The studies are conducted in compliance with Good laboratory practices (GLP). DRF has an expertise and a year of experience to handle PRE-IND projects. Our Scientist led by Ph.D. provide guidance to support your IND submissions.

Know More

The department of Genetic Toxicology is highly equipped to help our clients address their concerns regarding that several substances stimulate mutations in experimental systems. Various tests based on expanded mutagenic impacts have been recommended by OECD, as well as OPPTS (OCPSS), for evaluation of mutagenic potential of the test chemicals. DRF conducts the following tests strictly adhering to required guidelines:
In Vitro
  • Bacterial Reverse Mutation Test (Ames test) using Salmonella typhimurium and E. coli WP2uvrA
  • In Vitro Mammalian Chromosome Aberration Test using Chinese Hamster Ovary – K1 cell line
In Vivo
  • In Vivo Mammalian Erythrocyte Micronucleus Test in Mice/Rat (With and without toxicokinetic)
A technically experienced team of scientists at DRF carry out in vitro ADME and in vivo Pharmacokinetic/ Toxicokinetics along with a well supported bioanalytical group to expedite the discovery process for the sponsor. The services offered include –
ADME
Pharmacokinetics
Bioanalytical
Analytical
Background
Adult human mesenchymal stem cells (hMSC) are rare fibroblast-like cells capable of differentiating into a variety of cell types including bone, cartilage, and fat cells. The International Society for Cell Therapy (ISCT) has recommended a specific cell surface signature for MSCs. Conventional surface markers used to define hMSCs are CD73, CD90, and CD105 positive and CD14, CD19, CD34, CD45 and HLA-DR negative. Immunophenotype as measured by flow cytometry is among the criteria for identifying hMSC proposed by ISCT, which states that =95% of the hMSC population must express CD105, CD73, and CD90 and the same cells must lack (= 2% positive) expression of CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR. At DRF, MSCs can be characterized by immunophenotyping using flow cytometry (Guava flow cytometer).
At DRF, biomarker estimation using Multiplex platforms is built by robust and well known Luminex xMAP technology. We can simultaneously detect different analytes offering significant cost saving and increased amount of information with limited sample adding value to early discovery research. We perform the multiplex study in diverse matrices such as a serum, plasma, and tissue culture supernatants.
The various panels available with us include:
  • Human Inflammation Assays
  • Human MMP and TIMP Assays
  • Cytokine, Chemokine, and Growth Factor Assays- Human/Mouse/Rat
  • Diabetes, Metabolic, and Hormone Assays- Human/Mouse/Rat
  • Kidney Toxicity Assays- Human/Rat/Canine
  • Disease Research Assays-Human-Cancer; Cytokine; Acute phase; Isotyping
  • Cell Signaling Assays
  • Apoptosis Assays
  • Get A Quote

    Get A Quote